JP2006514024A - Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法 - Google Patents

Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法 Download PDF

Info

Publication number
JP2006514024A
JP2006514024A JP2004561407A JP2004561407A JP2006514024A JP 2006514024 A JP2006514024 A JP 2006514024A JP 2004561407 A JP2004561407 A JP 2004561407A JP 2004561407 A JP2004561407 A JP 2004561407A JP 2006514024 A JP2006514024 A JP 2006514024A
Authority
JP
Japan
Prior art keywords
antibody
cells
pharmaceutical composition
nkp30
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004561407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514024A5 (https=
Inventor
ロマネ，フランソワ
アンドレ，パスカル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2006514024A publication Critical patent/JP2006514024A/ja
Publication of JP2006514024A5 publication Critical patent/JP2006514024A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004561407A 2002-12-23 2003-12-22 Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法 Pending JP2006514024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43534402P 2002-12-23 2002-12-23
PCT/EP2003/014716 WO2004056392A1 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same

Publications (2)

Publication Number Publication Date
JP2006514024A true JP2006514024A (ja) 2006-04-27
JP2006514024A5 JP2006514024A5 (https=) 2007-02-08

Family

ID=32682222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004561407A Pending JP2006514024A (ja) 2002-12-23 2003-12-22 Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法

Country Status (6)

Country Link
US (1) US20080063717A1 (https=)
EP (1) EP1575615A1 (https=)
JP (1) JP2006514024A (https=)
AU (1) AU2003294930B2 (https=)
CA (1) CA2510787A1 (https=)
WO (1) WO2004056392A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140051263A (ko) * 2011-06-24 2014-04-30 고쿠리쓰다이가쿠호진 규슈다이가쿠 Nk 세포의 증폭 방법
JP2017012010A (ja) * 2015-06-26 2017-01-19 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
CN111304248A (zh) * 2018-12-25 2020-06-19 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
WO2022080894A1 (ko) * 2020-10-16 2022-04-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
US12345068B2 (en) 2021-11-19 2025-07-01 Sundance Spas, Inc. Self-maintaining hot tub or spa

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105848A1 (en) * 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
EP2947144B1 (en) * 2013-01-15 2020-09-09 Hiroyuki Abe Method for manufacturing immunocyte-containing composition, and cancer-treating composition
EP2824112B1 (en) 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
CN105462923B (zh) * 2014-12-17 2018-11-02 山东大学第二医院 一种人自然杀伤细胞体外高效扩增方法
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
CN115925933A (zh) * 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3032249A1 (en) * 2016-08-17 2018-02-22 University Health Network Regulation of tumor-associated t cells
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224681A1 (en) * 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021143858A1 (en) * 2020-01-17 2021-07-22 Beigene, Ltd. ANTI-NKp30 ANTIBODIES AND METHODS OF USE
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140051263A (ko) * 2011-06-24 2014-04-30 고쿠리쓰다이가쿠호진 규슈다이가쿠 Nk 세포의 증폭 방법
KR101963920B1 (ko) 2011-06-24 2019-03-29 고쿠리쓰다이가쿠호진 규슈다이가쿠 Nk 세포의 증폭 방법
JP2017012010A (ja) * 2015-06-26 2017-01-19 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
CN111304248A (zh) * 2018-12-25 2020-06-19 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
US11234421B2 (en) 2018-12-25 2022-02-01 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric IL15
WO2022080894A1 (ko) * 2020-10-16 2022-04-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
WO2022102887A1 (ko) * 2020-11-11 2022-05-19 한바이오 주식회사 Nk 세포의 대량증식 배양방법
JP2023548969A (ja) * 2020-11-11 2023-11-21 ハンビオ シーオー．，エルティーディー． Ｎｋ細胞の大量増殖培養方法
JP7589365B2 (ja) 2020-11-11 2024-11-25 ハンビオ シーオー．，エルティーディー． Ｎｋ細胞の大量増殖培養方法
US12345068B2 (en) 2021-11-19 2025-07-01 Sundance Spas, Inc. Self-maintaining hot tub or spa

Also Published As

Publication number Publication date
CA2510787A1 (en) 2004-07-08
US20080063717A1 (en) 2008-03-13
EP1575615A1 (en) 2005-09-21
AU2003294930A1 (en) 2004-07-14
WO2004056392A1 (en) 2004-07-08
AU2003294930B2 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
JP2006514024A (ja) Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
CN113543799B (zh) 靶向dll3的嵌合抗原受体和结合剂
KR102593475B1 (ko) 면역치료용 조성물 및 방법
US12447178B2 (en) Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors
TW202011999A (zh) Dll3 的嵌合受體及其使用方法
KR20200071753A (ko) 키메라 항원 수용체 면역요법제를 투여하는 방법
CN112771080B (zh) 针对steap1的嵌合受体及其使用方法
US20230190798A1 (en) Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
JP2018516881A (ja) 癌治療のためのｎｋ細胞および抗体
JP2019513836A (ja) 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法
US20250171731A1 (en) Methods of manufacturing allogeneic car t cells
WO2003038062A2 (en) Generation of use of tc1 and tc2 cells
JP2024091728A (ja) Ｔ細胞の拡張及び活性化の方法
JP2022526856A (ja) 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法
JPH08509859A (ja) ＴＧＦ−βの中和による長期骨髄培養物における幹細胞の拡大
JP2025540077A (ja) ナチュラルキラー細胞エンゲージャー
Scibienski et al. Establishment and initial characterization of continuous in vitro cultures of bovine T lymphocytes
RU2828787C2 (ru) Способы получения аллогенных t-клеток с car
HK40124206A (zh) 用於抑制hhv-6感染的体外方法
HK40105171A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
KR20230142760A (ko) Car t 세포 의약품의 제형 및 프로세스
KR20230171919A (ko) Ccr4 표적화 키메라 항원 수용체 세포 요법
HK40071084A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
HK40071084B (en) Rituximab-resistant chimeric antigen receptors and uses thereof
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100629